natgillin/translations-raw huggingface dataset:
Zlasti v primeru področij, ki so pomembna za industrijo, je določitev tem med drugim slonela na delu različnih „evropskih tehnoloških platform“, vzpostavljenih na področjih, kjer so konkurenčnost, gospodarska rast in dobrobit Evrope srednjeročno do dolgoročno odvisni od pomembnega napredka na področju raziskav in tehnologije.
In the case of subjects of industrial relevance in particular, the topics have been identified relying, among other sources, on the work of different “European Technology Platforms” set up in fields where Europe’s competitiveness, economic growth and welfare depend on important research and technological progress in the medium to long term.
Evropske tehnološke platforme pod vodstvom industrije združujejo zainteresirane strani z namenom določitve in izvajanja Agende strateškega raziskovanja.
European Technology Platforms bring together stakeholders, under industrial leadership, to define and implement a Strategic Research Agenda.
Ta okvirni program bo prispeval k uresničitvi teh agend strateškega raziskovanja, v kolikor te predstavljajo pravo evropsko dodano vrednost.
This Framework Programme will contribute to the realisation of these Strategic Research Agendas where these present true European added value.
Podpora agend strateškega raziskovanja industrij ni naloga okvirnega programa.
It is not the job of the Framework Programme to serve industry's strategic research agendas.
Priloga I, del I, „Sodelovanje“, odstavek 10
Annex I, Part I, "Cooperation", paragraph 10
Etična načela , vprašanja dostopnosti in vidik enakopravnosti med spoloma se bodo ustrezno in horizontalno upoštevali pri vseh zadevnih temah v zvezi z raziskavami .
Ethical principles , accessibility issues and gender aspects will be duly and horizontally taken into account in all relevant research themes .
Novo razvite tehnologije bodo sicer ustvarile nove ovire za številne evropske državljane; če pa se takšna vprašanja obravnavajo med načrtovanjem, se zagotavlja popolna dostopnost z omejenim vlaganjem (navadno 2–4 % celotnega proračuna za vsak nov projekt).
Newly developed technologies will otherwise create new barriers to many European citizens; whereas if such issues are considered at the design phase, full accessibility will be guaranteed with only limited investment (typically 2-4% of the overall budget of each new project).
Priloga I, del I, „Skupne tehnološke pobude“, odstavek 1
Annex I, Part I, "Joint Technology Initiatives", paragraph 1
Te pobude, ki večinoma izhajajo iz dela evropskih tehnoloških platform in zajemajo en vidik ali majhno število izbranih vidikov raziskav na njihovem področju, bodo združevale naložbe zasebnega sektorja in javno financiranje na nacionalni in evropski ravni, vključno s financiranjem z nepovratnimi sredstvi iz okvirnega raziskovalnega programa in financiranjem posojil s strani Evropske investicijske banke.
These initiatives, mainly resulting from the work of European Technology Platforms and covering one or a small number of selected aspects of research in their field, will combine private sector investment and national and European public funding, including grant funding from the Research Framework Programme and loan finance from the European Investment Bank.
Vsako skupno tehnološko pobudo je treba odobriti s posameznim Sklepom Sveta, da bi zagotovili večjo stopnjo pravičnosti (v gospodarskem in tehnološkem smislu) med različnimi državami članicami.
Each Joint Technology Initiative must be approved by means of an individual Council decision in order to ensure that there is a greater degree of fairness (in both economic and technological terms) amongst the various Member States.
Podpora teh vrst struktur ne sme povzročiti povečanja tehnoloških in gospodarskih nesorazmerij med državami članicami.
Support for structures of this kind should not lead to an increase in the technological and economic disparities amongst the Member States.
Priloga I, del I „Skupne tehnološke pobude“, odstavek 3
Annex I, Part I, "Joint Technology Initiatives", paragraph 3
Posebna pozornost bo namenjena sodelovanju MSP in raziskovalnih inštitutov v takšnih pobudah ter splošni medsebojni odvisnosti in uskladitvi med skupnimi tehnološkimi pobudami ter nacionalnimi programi in projekti na istih področjih.
Particular attention will be paid to the participation of SMEs and research institutes in such initiatives and to the overall coherence and coordination between Joint Technology Initiatives and national programmes and projects in the same fields.
Sodelovanje MSP pri skupnih tehnoloških pobudah je resnično pomembno.
The participation of SMEs in Joint Technology Initiatives is indeed important.
Vseeno je sodelovanje raziskovalnih inštitutov enako pomembno za zagotavljanje, da raziskave, ki jih financira država, služijo industrijskim ter družbenim in javnim interesom.
Of equal importance however is the participation of Research Institutes in them, so as to guarantee that state-funded research serves not only the industrial but also societal and public interest.
V nasprotnem primeru lahko na primer STP industrije zanemarjajo varnost prometa na račun udobja voznika in povečanja obsega.
Otherwise, the industry-led JTI's may for example neglect traffic safety in the expense of driver's comfort and enhanced scales.
Priloga I, del I, „Mednarodno sodelovanje“, odstavek 1, zaporedna točka 2
Annex I, Part I, “International co-operation”, paragraph 1, bullet point 2
• Posebni ukrepi sodelovanja na vsakem od tematskih področij, namenjeni tretjim državam, v primeru skupnega interesa za sodelovanje pri posebnih temah.
• Specific co-operation actions in each thematic area dedicated to third countries in the case of mutual interest in co-operating on particular topics.
Med te ukrepe spadajo zlasti: ukrepi, namenjeni krepitvi raziskovalnih zmogljivosti držav kandidatk ter tudi sosednjih držav; dejavnosti sodelovanja, namenjene državam v razvoju in novim državam, s poudarkom na njihovih posebnih potrebah na področjih kot so zdravje, kmetijstvo, ribištvo in okolje, ter izvedene v finančnih pogojih, prilagojenih njihovim zmogljivostim.
Such actions are, in particular: actions aiming at reinforcing the research capacities of candidate countries as well as neighbourhood countries; cooperative activities targeted at developing and emerging countries, focusing on their particular needs in fields such as health, agriculture, fisheries and environment, and implemented in financial conditions adapted to their capacities.
Med te ukrepe spadajo zlasti: ukrepi, namenjeni krepitvi raziskovalnih zmogljivosti držav kandidatk ter tudi sosednjih držav; dejavnosti sodelovanja, namenjene državam v razvoju in novim državam, s poudarkom na njihovih posebnih potrebah na področjih , kot so zdravje, s posebnim poudarkom na redkih boleznih in zapostavljenih boleznih, kmetijstvo, ribištvo in okolje, ter izvedene v finančnih pogojih, prilagojenih njihovim zmogljivostim.
Such actions are, in particular: actions aiming at reinforcing the research capacities of candidate countries as well as neighbourhood countries; cooperative activities targeted at developing and emerging countries, focusing on their particular needs in fields such as health, with particular emphasis on orphan and neglected diseases, agriculture, fisheries and environment, and implemented in financial conditions adapted to their capacities.
Priloga I, del I, razdelek "Teme", točka 1 "Zdravje", podtočka "Cilj"
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Objective"
Izboljšanje zdravja evropskih državljanov in povečanje konkurenčnosti evropskih industrijskih sektorjev in podjetij, povezanih z zdravjem , ob obravnavi svetovnih zdravstvenih problemov, vključno s pojavljajočimi se epidemijami.
Improving the health of European citizens and increasing the competitiveness of European health-related industries and businesses, while addressing global health issues including emerging epidemics.
Izboljšanje telesnega in duševnega zdravja evropskih državljanov in prispevek k učinkovitosti evropskega zdravstvenega sektorja ob podpori konkurenčnosti podjetij, povezanih s tem sektorjem, in obravnavi svetovnih zdravstvenih problemov, vključno s pojavljajočimi se epidemijami, redkimi boleznimi in zapostavljenimi boleznimi .
Improving the physical and mental health of European citizens and contributing to the performance of the European health sector , while supporting the competitiveness of businesses related to that sector and addressing global health issues including emerging epidemics , orphan diseases and neglected diseases .
Raziskave bodo usmerjene tako v preprečevanje bolezni kot v razvijanje učinkovitega zdravljenja in zdravil ob zagotavljanju pravičnega dostopa do rezultatov javno financiranih raziskav.
Research will aim both at the prevention of diseases and the development of effective treatments and medicines while ensuring equitable access to results of publicly funded research.
Poudarek bo na translacijskih raziskavah (prenos temeljnih odkritij v prakso na klinični ravni in na ravni populacije ), na razvijanju in potrjevanju novih terapij, metod za spodbujanje zdravja in preventivo, diagnostičnega orodja in tehnologij, tehnologij za zdravo staranje ter tudi na trajnostnih, dostopnih in učinkovitih sistemih zdravstvenega varstva.
Emphasis will be put on translational research (translation of basic discoveries in applications at clinical and population level ), the development and validation of new therapies, methods for health promotion and prevention, diagnostic tools and technologies, technologies for healthy ageing as well as sustainable , accessible and efficient healthcare systems.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Utemeljitev“, odstavek 2
Annex I, Part I, Section"Themes", Point 1 "Health", Subpoint "Rationale", paragraph 2
Klinične raziskave številnih bolezni (npr. rak, bolezni srca in ožilja, dihalne, revmatične bolezni, duševne in nevrološke bolezni, zlasti tiste, povezane s staranjem, kot sta Alzheimerjeva in Parkinsonova bolezen , in nenalezljive bolezni, povezane z zdravjem otrok ) temeljijo na mednarodnih poskusih v več centrih, da bi v kratkem časovnem okviru dobili zahtevano število pacientov.
Clinical research on many diseases (e.g. cancer, cardiovascular diseases, respiratory diseases, rheumatic diseases , mental and neurological diseases, in particular those linked with ageing, such as Alzheimer and Parkinson diseases , and non-transmissible diseases linked to children's health ), relies on international multi-centre trials to achieve the required number of patients in a short time-frame.
Epidemiološke raziskave , katerih namen je določiti bolezenske dejavnike na ravneh od molekularnih do družbenih dejavnikov, zahtevajo veliko raznovrstnost populacij in mednarodnih omrežij, da bi prišli do pomembnih ugotovitev.
Epidemiological research aimed at identifying disease determinants at levels ranging from the molecular to the social requires a large diversity of populations and international networks to achieve significant conclusions.
Razvijanje novih možnosti za diagnosticiranje in zdravljenje redkih zdravstvenih motenj ter izvajanje epidemioloških raziskav o teh motnjah prav tako zahteva večdržavne pristope, da bi povečali število pacientov za vsako študijo.
Developing new diagnostics and treatments for rare disorders and carrying out epidemiological research into such disorders also require multi-country approaches to increase the number of patients for each study.
Izvajanje raziskav, ki jih usmerja zdravstvena politika, na evropski ravni omogoča primerjave modelov, sistemov, podatkov in vzorcev pacientov, shranjenih v nacionalnih podatkovnih zbirkah in biobankah , vključno z javnimi bankami za izvorne celice iz krvi popkovine .
And performing health policy-driven research at the European level enables comparisons of the models, systems, data, and patient material held in national databases and biobanks , including public banks of stem cells taken from umbilical cord blood .
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Utemeljitev“, odstavek 3
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Rationale", paragraph 3
Obsežne biomedicinske raziskave na ravni EU bodo pomagale okrepiti konkurenčnost evropske biotehnologije na področju zdravstvenega varstva, medicinske tehnologije in farmacevtske industrije.
A strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries.
EU mora igrati dejavno vlogo tudi pri ustvarjanju okolja, ki spodbuja inovativnost v farmacevtskem sektorju, zlasti pri doseganju čim večjega uspeha kliničnih raziskav.
The EU also has to play an active role in creating an environment conducive to innovation in the pharmaceutical sector, in particular to maximise the success of clinical research.
MSP, dejavna na področju raziskav, predstavljajo glavno gospodarsko gonilno silo za industrijo biotehnologije na področju zdravstvenega varstva in medicinske tehnologije.
Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries.
Čeprav ima Evropa trenutno več družb na področju biotehnologije kot ZDA, so le-te večinoma majhne in manj zrele od njihovih konkurentov.
Although Europe now has more Biotechnology companies than US, most of them are small and less mature than their competitors.
Javno-zasebna raziskovalna prizadevanja na ravni EU bodo olajšala njihov razvoj.
Public-private research efforts at the EU level will facilitate their development.
Raziskave EU bodo prispevale tudi k razvoju novih normativov in standardov za vzpostavitev ustreznega pravnega okvira za nove medicinske tehnologije (npr. regenerativna medicina).
EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine).
Obsežne biomedicinske raziskave na ravni EU bodo pomagale izboljšati zdravje in okrepiti konkurenčnost evropske biotehnologije na področju zdravstvenega varstva, medicinske tehnologije in farmacevtske industrije.
A strong EU-based biomedical research will help to improve health and to strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries.
Čeprav ima Evropa zdaj več družb na področju biotehnologije kot ZDA, so le-te večinoma majhne in manj zrele od njihovih konkurentov.
Although Europe now has more Biotechnology companies than US, most of them are small and less mature than their competitors.
Evropske raziskave in inovacije na področju nadomestnih preskusnih strategij in zlasti metod, ki ne vključujejo živali, bodo zagotovile globalno vodstvo pri obravnavi javnih skrbi in skrbi interesnih skupin v zvezi s stalno uporabo živali v biomedicinskih raziskavah in lahko razen tega zagotovijo trg za industrijske sektorje .
European research and innovation in the field of a lternative testing strategies and in particular non-animal methods will ensure global leadership in addressing public and stakeholder concerns about the continuing use of animals in biomedical research and could in addition provide a market for industry sectors.
V skladu z načelom subsidiarnosti bodo sredstva Skupnosti za raziskave osredotočena na raziskave izvornih celic odraslih ljudi in izvornih celic iz popkovine ter ne bodo preprečila uporabe odvečnih zarodkov, ki jih je treba uničiti, za raziskave zdravljenja.
In accordance with the subsidiarity principle, Community research funding will focus on adult stem-cell research and umbilical-cord stem-cell research and will not prevent supernumerary embryos which are due to be destroyed from being used for research into treatments.
V skladu s členom 18 Konvencije Sveta Evrope o človekovih pravicah in biomedicini (Konvencija iz Ovieda, 1997) se zarodki ne smejo pridobivati v raziskovalne namene.
Pursuant to Article 18 of the Council of Europe Convention on Human Rights and Biomedicine (1997 Oviedo Convention), embryos may not be produced for research purposes .
Zaželeno je spodbujanje vzpostavitve programa MICE (Preiskava zdravil za otroke Evrope) v skladu z Uredbo (ES) št. …/… o zdravilih za pediatrične namene o spremembi Uredbe Sveta (EGS) št. 1768/92, Direktive 2001/83/ES in Uredbe(ES) št. 726/2004.
I t is desirable to encourage the creation of the MICE (Medicines Investigation for the Children of Europe ) programme pursuant to Regulation (EC) No …/… on medicines used for paediatric purposes, amending Council Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004.
Listina Evropske unije o temeljnih pravicah, ki je bila razglašena v Nici (Francija) 7. decembra 2000, izrecno prepoveduje evgenične postopke in reproduktivno kloniranje, vendar pa izrecno ne omenja raziskav zarodkov (člen 3)
The Charter of Fundamental Rights of the European Union, which was proclaimed in Nice (France) on 7 December 2000, explicitly prohibits eugenic practices and reproductive cloning, but does not comment explicitly on embryo research (Article 3)
– „(...) v skladu z ustreznimi mednarodnimi konvencijami in kodeksi ravnanja, npr.
– "(...) in accordance with relevant international conventions and codes of conduct, e.g.
(…) Konvencija Sveta Evrope o človekovih pravicah in biomedicini, ki je bila podpisana v Oviedu 4. aprila 1997, in Dodatni protokol o prepovedi kloniranja človeških bitij, ki je bil podpisan v Parizu 12. januarja 1998“
(…) the Convention of the Council of Europe on Human Rights and Biomedicine signed in Oviedo on 4 April 1997, and the Additional Protocol on the Prohibition of Cloning Human Beings signed in Paris on 12 January 1998 ”
Treba je vztrajati pri podpori Parlamenta za vzpostavitev programa MICE v okviru sedmega okvirnega programa za raziskave in razvoj.
It is important to insist on Parliament's position in favour of the creation of the MICE programme under the Seventh FPRD.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Utemeljitev“, odstavek 4
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Rationale", paragraph 4
V nadaljevanju so navedene dejavnosti, ki bodo obravnavane in ki vključujejo raziskave, bistvene s političnega vidika.
The activities that will be addressed, which include research essential to policy requirements, are set out below.
Dve strateški vprašanji , zdravje otrok in zdravje starajočega se prebivalstva, bosta obravnavani v okviru več dejavnosti.
Two strategic issues, child health and the health of the ageing population will be addressed across activities.
Kot dopolnitev teh in kot odgovor na nove politične potrebe se bo lahko podprlo dodatne ukrepe, na primer na področju vprašanj zdravstvene politike ter varnosti in zdravja pri delu.
To complement these and respond to new policy needs, additional actions may be supported for example in the areas of health policy issues and occupational health and safety.
Tri strateška vprašanja , zdravje otrok , zdravje žensk in zdravje starajočega se prebivalstva, bodo obravnavana v okviru več dejavnosti.
Three strategic issues, child health, women's health and the health of the ageing population, will be addressed across activities.
Obstaja posebna potreba po določitvi in raziskavi potreb podpopulacij, vključno z invalidnimi osebami, manjšinami in prikrajšanimi skupinami.
There is a particular need to address and to investigate the needs of sub-populations, including disabled persons, minority groups and disadvantaged groups.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Dejavnosti“, podnaslov 1 „Biotehnologija, generična orodja in tehnologije za človekovo zdravje“, alinea 1
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Activities", subheading 1 "Biotechnology, generic tools and technologies for human health", indent 1
– Zahtevne proizvodne raziskave.
- High-throughput research.
Pospeševanje eksperimentalnega napredka v biomedicinskih raziskavah z izboljšanjem postopka priprave, standardizacije, pridobivanja in analiziranja podatkov.
To catalyse experimental progress in biomedical research by enhancing data generation, standardisation, acquisition and analysis.
Skupaj z osnovnimi raziskavami na področju nevrobiologije in behavioristične biologije, genetike in genomike za zdravje ljudi in živali.
Together with basic research on neurobiology and behaviour biology, genetics and genomics for human and animal health .
Zdajšnja raziskava je pokazala potrebo po vlaganju v osnovne raziskave na področju nevrologije, ki je temelj za biološko znanost in poznavanje človeških bitij.
Current research has proven the need to invest on basic research on neuroscience, as the cornerstone for bioscience and the knowledge of human beings.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Dejavnosti“, podnaslov 1 „Biotehnologija, generična orodja in tehnologije za človekovo zdravje“, alinea 2
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Activities", subheading 1 "Biotechnology, generic tools and technologies for human health", indent 2
Prednost je treba dati diagnostičnim orodjem, ki so neposredno povezana s terapijo .
Priority should be given to diagnostic tools that are directly linked to therapy.
Zato je treba dati prednost raziskavam, ki obravnavajo to težavo.
That's why research activities which address this problem should get a priority.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Dejavnosti“, podnaslov 1 „Biotehnologija, generična orodja in tehnologije za človekovo zdravje“, alinea 3
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Activities", subheading 1 "Biotechnology, generic tools and technologies for human health", indent 3
– Predvidevanje primernosti, varnosti in učinkovitosti terapij.
- Predicting suitability, safety and efficacy of therapies.
Razvijanje in potrjevanje bioloških označevalcev, metod in modelov in vitro, vključno s simulacijo, farmakogenomiko, ciljno usmerjenimi pristopi in drugimi nadomestnimi možnostmi za preskuse na živalih , zlasti za nadomeščanje uporabe primatov, razen človeka .
To develop and validate biological markers, in vitro methods and models, including simulation, pharmacogenomics, targeting approaches and other alternatives to animal testing , in particular to replace the use of non-human primates .
Razen tega sta Evropska komisija in Svet večkrat izjavila zavezanost zmanjševanju in nadomeščanju uporabe primatov, razen človeka, v raziskavah, kot na primer v preambuli Sklepa Sveta 1999/575/ES o evropski konvenciji za zaščito živali, ki se uporabljajo v raziskavah.
In addition, the European Commission and Council have repeatedly stated their commitment to reduce and replace the use of non-human primates in r e search, such as in the Preamble to Council Decision 1999/575/EC on the European Convention for the protection of animals used in research.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Dejavnosti“, podnaslov 1 „Biotehnologija, generična orodja in tehnologije za človekovo zdravje“, alinea 4
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Activities", subheading 1 "Biotechnology, generic tools and technologies for human health", indent 4
Inovativni terapevtski pristopi in posegi.
Innovative therapeutic approaches and intervention.
Priloga I, del I, oddelek „Teme“, točka 1 „Zdravje“, podtočka „Dejavnosti“, podnaslov 2 „Translacijske raziskave, ki služijo človekovemu zdravju“, alinea 2
Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Activities", subheading 2 "Translating research for human health", indent 2
– Raziskave možganov in z njimi povezanih bolezni, človekovega razvoja in staranja.
- Research on the brain and related diseases, human development and ageing.
Raziskovanje procesa zdravega staranja in načina, kako geni in okolje medsebojno vplivajo na delovanje možganov v normalnih pogojih ter tudi v primeru možganskih bolezni.
To explore the process of healthy ageing and the way genes and environment interact with brain activity, under normal conditions as well as in brain diseases.